SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma reports 7% fall in Q4 consolidated net profit

31 May 2021 Evaluate

Aurobindo Pharma has reported results for fourth quarter and year ended March 31, 2021.

The company has reported a rise of 21.59% in its net profit at Rs 872.58 crore for the quarter under review as compared to Rs 717.64 crore for the same quarter in the previous year. Total income of the company increased by 15.46% at Rs 4,381.45 crore for Q4FY21 as compared Rs 3,794.89 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a fall of 7.22% in its net profit attributed to the owners at Rs 801.58 crore for the quarter under review as compared to Rs 864 crore for the same quarter in the previous year. Total income of the company decreased by 1.80% at Rs 6,079.60 crore for Q4FY21 as compared Rs 6,191.02 crore for the corresponding quarter previous year.

For the year ended March 31, 2021, the company has reported a rise of 65.86% in its net profit at Rs 3,112.91 crore as compared to Rs 1,876.88 crore for the previous year. Total income of the company increased by 20.56% at Rs 16,413.54 crore for year under review as compared to Rs 13,614.20 crore for year ended March 31, 2020.

For the year ended March 31, 2021, on the consolidated basis, the company has reported a rise of 87.51% in its net profit attributed to the owners at Rs 5,334.85 crore as compared to Rs 2,845.13 crore for the previous year. Total income of the company increased by 8.50% at Rs 25,155.47 crore for year under review as compared to Rs 23,184.70 crore for year ended March 31, 2020.

Aurobindo Pharma Share Price

1391.15 23.45 (1.71%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×